STOCK TITAN
  1. Home
  2. Sec-filings
  3. ANTX
  4. [Form 4] AN2 Therapeutics, Inc. Insider Trading Activity

AN2 Therapeutics (NASDAQ: ANTX) insider RSU tax share sale details

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

AN2 Therapeutics officer reports small stock sales tied to RSU taxes. Chief Operating Officer and Chief Legal Officer Joshua M. Eizen reported selling 17,923 shares of AN2 Therapeutics common stock on January 5, 2026 at a weighted average price of $1.0014 per share, followed by 6,931 shares on January 6, 2026 at $1.012 per share. According to the footnotes, these shares were sold pursuant to the terms of the equity grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units on January 1, 2026. After the reported transactions, Eizen directly beneficially owned 152,499 shares of common stock, which include multiple RSU awards that vest over several years, subject to his continued service.

Positive

  • None.

Negative

  • None.
Insider Eizen Joshua M
Role See Remarks
Sold 24,854 shs ($25K)
Type Security Shares Price Value
Sale Common Stock 6,931 $1.012 $7K
Sale Common Stock 17,923 $1.0014 $18K
Holdings After Transaction: Common Stock — 152,499 shares (Direct)
Footnotes (1)
  1. Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026. This transaction was executed in multiple trades at prices ranging from $1.001 to $1.003 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Includes (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 60,000 RSUs which vest as follows: 25% of the RSUs vest on January 1, 2025, 50% of the RSUs vest on January 1, 2026, and 25% of the RSUs vest on July 1, 2026, (c) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, and (d) 58,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service as of such date.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Eizen Joshua M
(Last) (First) (Middle)
C/O AN2 THERAPEUTICS, INC.
1300 EL CAMINO REAL, SUITE 100
(Street)
MENLO PARK CA 94025
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
See Remarks
3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 01/05/2026 S 17,923(1) D $1.0014(2) 159,430(3) D
Common Stock 01/06/2026 S 6,931(1) D $1.012 152,499(3) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026.
2. This transaction was executed in multiple trades at prices ranging from $1.001 to $1.003 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
3. Includes (a) 30,000 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024, (b) 60,000 RSUs which vest as follows: 25% of the RSUs vest on January 1, 2025, 50% of the RSUs vest on January 1, 2026, and 25% of the RSUs vest on July 1, 2026, (c) 31,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from November 4, 2024, and (d) 58,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person's continuous service as of such date.
Remarks:
Chief Operating Officer and Chief Legal Officer
/s/ Lucy Day, Attorney-in-Fact for Joshua M. Eizen 01/07/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did AN2 Therapeutics (ANTX) report in this Form 4?

The filing reports that officer Joshua M. Eizen sold 17,923 shares of AN2 Therapeutics common stock on January 5, 2026 and 6,931 shares on January 6, 2026 at prices around $1.00 per share.

Why did Joshua Eizen sell AN2 Therapeutics (ANTX) shares?

A footnote states the shares sold represent stock disposed of to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units (RSUs) on January 1, 2026.

What prices were the AN2 Therapeutics (ANTX) insider sales executed at?

The January 5, 2026 sale had a weighted average price of $1.0014 per share, based on multiple trades between $1.001 and $1.003. The January 6, 2026 sale was at $1.012 per share.

How many AN2 Therapeutics (ANTX) shares does Joshua Eizen hold after these sales?

Following the January 6, 2026 transaction, Joshua M. Eizen beneficially owned 152,499 shares of AN2 Therapeutics common stock in direct form.

What role does the reporting person hold at AN2 Therapeutics (ANTX)?

The remarks identify Joshua M. Eizen as AN2 Therapeutics' Chief Operating Officer and Chief Legal Officer.

What RSU grants are associated with Joshua Eizen’s AN2 Therapeutics (ANTX) holdings?

A footnote explains his holdings include RSUs totaling 30,000, 60,000, 31,500, and 58,500 units, each vesting in scheduled installments from January 1, 2024, January 1, 2025, November 4, 2024, and January 1, 2025, subject to continued service.